Ureaplasma parvum and Urealyticum: What’s the Difference and Which is More Pathogenic?

When discussing Ureaplasma spp., many recognize it as a bacterium detected during gynecological or urological health screenings. However, it’s less commonly known that Ureaplasma is primarily divided into two key species: Ureaplasma parvum and Ureaplasma urealyticum. Although they belong to the same genus, they differ significantly in prevalence, pathogenic potential, and health implications.

This article provides a clear, evidence-based comparison of these two species. Whether you were diagnosed incidentally, are asymptomatic, planning a pregnancy, or undergoing fertility treatment, this information will help you understand your situation and make informed decisions with your healthcare provider.

What Are Ureaplasma parvum and Ureaplasma urealyticum, and How Do They Differ?

Ureaplasma parvum and Ureaplasma urealyticum are small, cell wall-less bacteria belonging to the genus Ureaplasma and the family Mycoplasmataceae. Both species are found exclusively in humans, but despite being closely related, they have important biological and genetic distinctions.

• Nomenclature Origin: Historically, Ureaplasma was classified into biovars based on serotypes.
  • Ureaplasma parvum: Formerly known as Biovar 1 (comprising serovars 1, 3, 6, 14).
  • Ureaplasma urealyticum: Formerly known as Biovar 2 (comprising serovars 2, 4, 5, 7, 8, 9, 10, 11, 12, 13).
• Key Genetic Differences:
  • Genome Size: U. parvum has a slightly smaller genome than U. urealyticum, suggesting lower genetic plasticity.
  • Surface Protein Variability: U. urealyticum exhibits significantly greater diversity in its surface proteins. This allows it to better evade the host’s immune system, which is a key factor in its higher pathogenic potential.
• Defining Trait: Both species possess urease activity—the ability to break down urea, which gives the genus its name. However, the intensity of this activity can vary between strains.

In short: While they are from the same family, their genetic differences, especially in surface protein diversity, lead to distinct clinical behaviors and pathogenic potentials.

Which Is More Common: Parvum or Urealyticum?

Epidemiological data from the last decade consistently show that Ureaplasma parvum is significantly more prevalent than Ureaplasma urealyticum, especially in asymptomatic, reproductive-age women.

• Research Statistics: Studies show that overall, Ureaplasma spp. colonization rates can be as high as 40-60% in sexually active women.
  • Of these positive cases, Ureaplasma parvum accounts for approximately 65-85%.
  • In contrast, Ureaplasma urealyticum is found in only 15-35% of cases.
• Reason for Higher Prevalence: U. parvum‘s smaller, more stable genome may allow it to colonize the urogenital tract more easily without triggering a significant inflammatory response.

Key takeaway: Higher prevalence does not mean higher risk. Clinically, the less common U. urealyticum is often considered more medically significant due to its stronger association with disease.

Which Is More Pathogenic: Parvum or Urealyticum?

This is the most critical question for patients and clinicians. Evidence from numerous systematic reviews and meta-analyses provides a clear answer:

Ureaplasma urealyticum is more strongly and consistently associated with clinically significant diseases of the reproductive system than Ureaplasma parvum.

While U. urealyticum is the more pathogenic species, U. parvum is not entirely benign. It can become a problem, particularly at high bacterial loads or in individuals struggling with infertility. Therefore, clinical assessment must be individualized.

Which Species Is More Associated with Infertility?

When focusing specifically on infertility, the medical evidence points more strongly towards Ureaplasma urealyticum as a significant factor.

• In Women: U. urealyticum is linked to endometritis (inflammation of the uterine lining) and tubal disease, which can directly impair embryo implantation and fertility.
• In Men: U. urealyticum has been associated with poor sperm quality, including reduced motility and abnormal morphology, and may increase reactive oxygen species (ROS) that damage sperm DNA.
• The Role of U. parvum: Its role in infertility is less clear. While it is more common, it is generally considered a potential issue only when found in very high quantities in patients with unexplained infertility.

Recommendation: For individuals or couples planning to undergo Assisted Reproductive Technology (ART) like IVF or ICSI, many clinics recommend screening for and treating Ureaplasma (both species) to optimize success rates.

Are Testing and Treatment Different?

Testing:

• Sample Collection: The method is the same for both species. This involves a vaginal/cervical swab for women or a urethral swab/first-void urine sample for men.
• Laboratory Technique: This is where the difference lies. To distinguish between parvum and urealyticum, the lab must use a species-specific Polymerase Chain Reaction (PCR) test. A generic Ureaplasma PCR test will only report a positive or negative result for the genus without identifying the species.

Treatment:

• Identical. The treatment protocol for both species is the same. Because they lack a cell wall, they are treated with antibiotics that target protein synthesis.
• First-line Antibiotics:
  • Tetracyclines (e.g., Doxycycline)
  • Macrolides (e.g., Azithromycin, which is the preferred choice for pregnant women.
• Conclusion: There is no need for a different treatment protocol based on the species. A doctor’s choice of antibiotic will depend on the patient’s clinical status (e.g., pregnancy), allergy history, and local antibiotic resistance patterns.

Should I Worry If I Test Positive for Ureaplasma parvum?

A positive test for U. parvum, a very common bacterium, does not automatically mean you are sick or require treatment. The decision should be based on clinical context:

1. If you are asymptomatic: And not currently trying to conceive, there is generally no need for concern or treatment. The bacteria is likely acting as a harmless commensal.
2. If you have symptoms: Such as abnormal vaginal discharge, pelvic pain, or painful urination (dysuria), you should consult your doctor to discuss treatment.
3. If you are planning a pregnancy or undergoing IVF: Most guidelines recommend treatment to eliminate any potential risk factors that could affect outcomes.
4. If your results show a high bacterial load: Even without symptoms, this may warrant a discussion with your doctor about the potential risks and benefits of treatment.

Conclusion

Ureaplasma parvum and Ureaplasma urealyticum are distinct species with different clinical implications.

• Ureaplasma parvum: Is much more common and, in most cases, is a harmless member of the urogenital flora.
• Ureaplasma urealyticum: Is less common but has a well-established link to reproductive diseases and infertility.

The decision to treat should never be based on the presence of the bacteria alone. It requires a collaborative assessment between the patient and the doctor, considering symptoms, bacterial load, fertility goals, and other individual risk factors.

FAQ

1. How is this infection primarily transmitted?

Ureaplasma is primarily transmitted through sexual contact. However, it can also be passed from a mother to her child during childbirth. A positive test result does not always indicate a recent infection or infidelity, as the bacteria can reside in the body for years without causing any symptoms.

2. If I test positive, does my partner need treatment too? Yes, this is highly recommended.

Especially if you are symptomatic or undergoing fertility treatment, doctors will almost always advise treating both partners simultaneously. This is crucial to prevent the “ping-pong effect,” where you pass the infection back and forth, leading to treatment failure and reinfection.

3. Why do some people have the infection with no symptoms at all?

Whether the infection causes disease depends on a balance of three key factors

• Bacterial Load: If the quantity of bacteria is low, the body’s immune system can often keep it in check.
• Bacterial Species: U. urealyticum is more pathogenic than U. parvum.
• Host Immune System: A strong immune system is better at controlling the bacteria. Think of it like the normal bacteria on your skin; it’s harmless until there’s a break in the skin or your immune system is compromised.

4. Can I get reinfected after being cured? Yes.

Successful treatment clears the existing infection, but your body does not develop permanent immunity. You can be reinfected through sexual contact with a partner who has not been treated or with a new partner who carries the bacteria.

5. What is a “Test of Cure,” and is it necessary?

A “Test of Cure” is a follow-up test performed after treatment is completed to confirm that the infection has been successfully eradicated. It is strongly recommended for

• Individuals who remain symptomatic after treatment.
• Couples planning for pregnancy or undergoing ART (IVF/ICSI).
• Pregnant women.
• Patients with a history of recurrent infections. Typically, this test is performed 3-4 weeks after finishing the full course of antibiotics to avoid detecting dead bacterial DNA, which could lead to a false-positive result.

6. Can Ureaplasma become antibiotic-resistant? Yes, and this is a growing global concern.

Antibiotic resistance in Ureaplasma species is on the rise. Therefore, it is critically important to

• Complete the full course of antibiotics exactly as prescribed, even if your symptoms improve early.
• Never self-medicate or use leftover antibiotics from a previous illness.
• Always inform your doctor of any drug allergies and previous antibiotic treatments.

7. Is there a way to prevent this infection?

Completely preventing Ureaplasma infection can be difficult due to its high prevalence. However, you can significantly reduce your risk by

• Consistently using condoms greatly reduces the chance of transmission.
• Limiting your number of sexual partners.
• Maintaining good personal hygiene.
• Undergoing regular sexual health screenings, especially when changing partners.

• Facebook
• Twitter
• Line